
Study links Wegovy to higher risk of sudden vision loss vs Ozempic in GLP-1 drugs
A FDA adverse-event database analysis (2017–2024) suggests Wegovy users have about 4.7 times higher odds of ischemic optic neuropathy than Ozempic users, with no clear link for Rybelsus; findings are associations, not definitive risk estimates for all patients, and researchers call for prospective studies to guide prescribing and policy.












